Special Issue “Antibody Engineering for Cancer Immunotherapy”

Silvia Crescioli; Ann L. White; Sophia N. Karagiannis

doi:10.3390/antib11020029

Antibodies (Apr 2022)

Special Issue “Antibody Engineering for Cancer Immunotherapy”

Silvia Crescioli,
Ann L. White,
Sophia N. Karagiannis

Affiliations

Silvia Crescioli: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London SE1 9RT, UK
Ann L. White: UCB Celltech, Slough SL1 3WE, UK
Sophia N. Karagiannis: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London SE1 9RT, UK

DOI: https://doi.org/10.3390/antib11020029
Journal volume & issue: Vol. 11, no. 2
p. 29

Abstract

Read online

Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the treatment of non-Hodgkin lymphoma, antibody engineering for cancer immunotherapy has become a rapidly growing field, with almost 50 antibody therapeutics approved in the USA and EU and hundreds undergoing testing in clinical trials [...]

n/a

Published in Antibodies

ISSN: 2073-4468 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://www.mdpi.com/journal/antibodies

About the journal

Abstract

Keywords